Zacks Investment Research on MSN9h
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
NBC Los Angeles18h
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Morgan Stanley upgrades Zealand Pharma to Buy on ’long-term obesity potential’
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement - No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand") (NA ...
Clinical Trials Arena6d
Enrolment concludes in Zealand’s Phase IIb obesity therapy trial
Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.